MiNA Therapeutics: Leader in RNA activation (RNAa). RNAa platform address 3,500+ indications, capable of drugging any protein target to increase natural protein production in patients own cells. Validated lipid nanoparticle delivery technology (exclusive license with BioNTech), 50+ targets under evaluation in immuno-oncology and genetic rare disease pipeline, 2 clinical programs (10 expected by 2025), 1 ISS, 15 pre-clinical programs. Lead program MTL-CEPBA, first RNAa therapy to achieve clinical POC, restores CEPBA protein pathway (randomized Ph2 study with sorafenib in 2L HCC has 1Q23 interim/2Q24 final data and potential accelerated approval 2024, Ph1/1b study with MTL-CEBPA+Pembro in advanced solid tumors with primary resistance to anti-PD1). Second RNAa candidate MTL-STING reactivates innate immune responses (1Q23 IND filing). Genetic rare disease portfolio addressing MPS1 Hurler programs (Ph1/2 start 1Q23), complement deficiency, blood disorder. Partnerships with Eli Lilly, Servier ($1.5B+ payments). Key investors – aMoon, Eli Lilly.